Drug Profile
Research programme: cancer therapeutics - 4SC Discovery/Crelux/Ribological
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator 4SC Discovery; CRELUX; Ribological
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany
- 15 Apr 2016 CRELUX has been acquired by WuXi AppTec
- 17 Jul 2012 Early research in Cancer in Germany (unspecified route)